Global Monosialyltetrahexose Ganglioside Sodium Injection Market Size, Share and Trends Analysis Report, Application (Central Nervous System and Parkinson’s Disease) Forecast Period (2022-2028)

The global monosialyltetrahexose ganglioside sodium injection market is anticipated to grow at a CAGR of 4.2% during the forecast period (2022-2028). Traumatic brain injury is a leading cause of death and disability around the globe will propel the monosialyltetrahexose ganglioside sodium injection market growth. The annual incidence of traumatic brain injury is estimated to be between 27 and 69 million individuals globally. Many survivors have substantial disabilities, putting them at a significant socioeconomic disadvantage.

Another major factor for the growth of monosialyltetrahexose ganglioside sodium injection industry is diabetes, especially Type 2 diabetes, which is a global pandemic that affects hundreds of millions of people. The problems that may arise from this disease might have a significant influence on one’s quality of life. Diabetic neuropathy (DN) is the most prevalent consequence among diabetics and is caused by chronically elevated blood sugar levels. According to a study undertaken by the National Institutes of Health, at least half of all diabetics develop peripheral neuropathy at some point in their lives. According to other independent research, up to 70% of diabetics will develop diabetic neuropathy.

According to the Foundation for Peripheral Neuropathy, an estimated 30 million people in the US from peripheral neuropathy. Peripheral neuropathy is a broad term that encompasses a variety of conditions. It’s a catch-all phrase for a variety of illnesses caused by nerve injury in the body’s peripheral nervous system. Sensation, motor coordination, involuntary bodily activities, and other functions are all controlled by peripheral nerves. Motor nerves, sensory nerves, and autonomic nerves are the three types of peripheral nerves. Monosialyltetrahexose ganglioside sodium injection is used to treat peripheral neuropathy across the globe since as the prevalence of people suffering from peripheral neuropathy, the global market will rise in monosialyltetrahexose ganglioside sodium injection.

Some major players in the market include Beijing Science Sun Pharmaceutical Co., LTD., Qijian Bio-Pharmaceutical Co., Qilu pharmaceutical co.,ltd, Sihuan Pharmaceutical Holdings Group, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.

Company’s Products

Monosialotetrahexosylganglioside Sodium GM1 from Qijian Bio-Pharmaceutical Co. is a ganglioside that contains one sialic acid residue and belongs to the ganglio series of gangliosides. GM1 affects neuronal plasticity and repair mechanisms, as well as the release of neurotrophins in the brain, and has crucial physiological features. Aside from its role in brain physiology, GM1 serves as a binding site for cholera toxin and E.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-
  • By Application
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape- Beijing Science Sun Pharmaceutical Co., LTD., Qijian Bio-Pharmaceutical Co., Qilu pharmaceutical co.,ltd, Sihuan Pharmaceutical Holdings Group, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How has COVID-19 impacted the market?
  • Deviation from the pre-COVID-19 forecast
  • Most affected region and segment
• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Monosialyltetrahexose Ganglioside Sodium Injection Market Report by Segment

By Application

• Central Nervous System
• Parkinson’s Disease

Global Monosialyltetrahexose Ganglioside Sodium Injection Market Report by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa